EBMT 2016 | New monoclonal antibodies for ALL treatment
At the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, Arnon Nagler, MD, from Sheba Medical Center, Tel Hashomer, Israel discusses two monoclonal antibodies showing promise for the treatment of patients with acute lymphoblastic leukemia (ALL). Blinatumomab, a bispecific T cell engager (BiTE) antibody against CD19/CD3, is already used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory ALL. Inotuzumab ozogamicin, a CD22 monoclonal antibody bound to calicheamicin, is being evaluated in a phase 3 clinical trial, with data expected to be presented at the 21st Congress of the European Hematology Association (EHA) in Copenhagen, Denmark, June 2016.
